Methods for detecting FGFR3/TACC3 fusion genes

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9481911
SERIAL NO

14383199

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

[Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ASTELLAS PHARMA INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Asaumi, Makoto Tokyo, JP 8 40
Morinaka, Akifumi Tokyo, JP 9 33
Nishimura, Kouichi Tokyo, JP 74 670
Suzuki, Atsushi Tokyo, JP 542 5306
Tsunoyama, Kazuhisa Tokyo, JP 7 33
Yamauchi, Tomohiro Tokyo, JP 31 71
Yoshino, Masayasu Tokyo, JP 5 22
Yoshizaki, Hiroaki Tokyo, JP 2 21

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 1, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 1, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00